Table 1 Baseline of study population

Age, years

64.18 ± 7.42

63.27 ± 7.38

64.77 ± 7.39

<0.001

BMI, kg/m²

25.15 ± 3.29

24.98 ± 3.07

25.27 ± 3.43

<0.001

SBP, mmHg

129.08 ± 15.70

127.63 ± 15.74

130.03 ± 15.60

<0.001

DBP, mmHg

74.98 ± 11.83

73.88 ± 11.26

75.70 ± 12.14

<0.001

Smoking, n(%)

309 (6.50)

102 (5.43)

207 (7.20)

0.015

Drinking, n(%)

14 (0.29)

6 (0.32)

8 (0.28)

0.799

 DM, n (%)

1496 (31.47)

465 (24.75)

1031 (35.87)

<0.001

 HT, n (%)

3198 (67.28)

1191 (63.38)

2007 (69.83)

<0.001

 Hyperlipidemia, n(%)

1867 (39.28)

748 (39.81)

1119 (38.94)

0.547

 Family history of CVD, n(%)

242 (5.09)

115 (6.12)

127 (4.42)

0.009

 TC, mmol/L

4.46 ± 1.08

4.48 ± 1.04

4.45 ± 1.11

0.348

 TG, mmol/L

1.70 ± 1.14

1.63 ± 1.07

1.75 ± 1.18

<0.001

 LDL-C, mmol/L

2.63 ± 0.90

2.63 ± 0.86

2.62 ± 0.92

0.957

 HDL-C, mmol/L

1.13 ± 0.28

1.18 ± 0.30

1.10 ± 0.26

<0.001

 non-HDL-C, mmol/L

3.33 ± 1.04

3.30 ± 0.99

3.35 ± 1.07

0.141

 RLP-C, mmol/L

0.71 ± 0.45

0.68 ± 0.43

0.72 ± 0.47

0.001

 Aspirin

4109 (86.45)

1541 (82.01)

2568 (89.35)

<0.001

 Clopidogrel

2933 (61.71)

812 (43.21)

2121 (73.80)

<0.001

 Statins

3476 (73.13)

1360 (72.38)

2116 (73.63)

0.343

 β-blockers

2941 (61.88)

1092 (58.12)

1849 (64.34)

<0.001

 ARB

1005 (21.14)

369 (19.64)

636 (22.13)

0.040

 ACEI

242 (5.09)

74 (3.94)

168 (5.85)

0.003